Company profile
Tumour Antibody Penetration Technology - Creasallis
Company with a creative approach to science, improving existing antibodies with simple plug-and-play engineering - tumour antibody penetration technology.
Financial period: 1 Jul 2024 to 30 Jun 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
Company registered at Companies House
1 May 2024 to 30 Apr 2025
Monoclonal antibodies offer a successful targeted approach for cancer treatment due to their high specificity. Several efficacious drugs have come to market such as trastuzumab, ipilimimab, cetuximab, bevacizumab and pembroluzimab. However, these therapies benefit only a few. Limited penetrability of antibodies into the tumour have lead to high drug toxic...
